• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Onconetix Inc.

    11/14/24 11:19:35 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ONCO alert in real time by email
    SC 13G 1 ss4101599_sc13g.htm SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     



     

    Onconetix, Inc.
    (Name of Issuer)

     

     

    Common stock, par value $0.00001 per share
    (Title of Class of Securities)

     

    68237Q104

    (CUSIP Number)

     

    September 24, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

       

     

     

             
    1

    NAME OF REPORTING PERSONS

     Zurcher Kantonalbank

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

     
    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Switzerland

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    562,691

    6 SHARED VOTING POWER
    7

    SOLE DISPOSITIVE POWER

     

     562,691

    8

    SHARED DISPOSITIVE POWER

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    562,691

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.8%

    12

    TYPE OF REPORTING PERSON

     FI

     

     

       

     

     

     

    Item 1.   (a) Name of Issuer:
        Onconetix, Inc.

     

        (b) Address of Issuer’s Principal Executive Offices:

    201 E. Fifth Street, Suite 1900, Cincinnati, OH 45202

     

    Item 2.   (a) Name of Person Filing:

    Zurcher Kantonalbank

        (b) Address of Principal Business Office:

    BAHNHOFSTRASSE 9

    ZURICH, SWITZERLAND 8001

        (c) Citizenship:

    Switzerland

        (d) Title of Class of Securities:

    Common stock, par value $0.00001 per share

        (e) CUSIP No.:

             68237Q104

     

    Item 3.      

    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J)

     

    Item 4. Ownership:

    Ownership as of September 30, 2024 is incorporated by reference to items (5) – (9) and (11) of the cover page.

    Item 5. Ownership of Five Percent or Less of a Class.

    Not Applicable

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

     

    Not Applicable

     

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable

     

    Item 8. Identification and Classification of Members of the Group.

     Not Applicable

     

     

    Item 9. Notice of Dissolution of Group.

     Not Applicable

       

     

     

     

    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

       

     

     

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

     

       
           
      By: /s/ Matthias Nänni
        Name: Matthias Nänni
        Title: Senior Member of Management

     

     

       

     

     

     

    Get the next $ONCO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ONCO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ONCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Tarsh Simon acquired 39 shares and was granted 618 shares, increasing direct ownership by 65,700% to 658 units (SEC Form 4)

    4 - Onconetix, Inc. (0001782107) (Issuer)

    8/19/25 4:05:27 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Meier Thomas acquired 39 shares and was granted 618 shares (SEC Form 4)

    4 - Onconetix, Inc. (0001782107) (Issuer)

    8/19/25 4:05:25 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Oakley Andrew John acquired 20 shares and was granted 618 shares (SEC Form 4)

    4 - Onconetix, Inc. (0001782107) (Issuer)

    8/19/25 4:05:29 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONCO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.

    CINCINNATI, OH, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) ("Onconetix" or the "Company") a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men's health and oncology, announced the September 22, 2025 signing and closing of a private placement of (i) shares of the Company's Series D Convertible Preferred Stock, $0.00001 par value (the "Series D Preferred Stock"), and (ii) warrants (the "Warrants") to purchase up to an aggregate of 4,362,827 shares of the Company's common stock, $0.00001 par value per share (the "Common Stock"), for an aggregate purchase price of approximately $12.9 million

    9/26/25 8:30:00 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement

    CINCINNATI, OH & FORT LEE, NJ, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO), a commercial-stage biotechnology company focused on innovative solutions for men's health and oncology, and Ocuvex Therapeutics, Inc., a leader in ophthalmic innovation, today announced the mutual termination of their previously announced definitive merger agreement, dated July 16, 2025. After careful consideration and constructive dialogue, both companies have jointly determined that pursuing independent paths is in the best interests of their respective stakeholders. This decision reflects the strong commitment of both Onconetix and Ocuvex to advancing their respective missions and deliver

    9/26/25 8:15:00 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM

    CINCINNATI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men's health and oncology, today announced that its wholly owned subsidiary, Proteomedix AG ("Proteomedix") has  signed a licensing agreement, with Immunovia AB, a pancreatic cancer diagnostics company based in Lund, Sweden. Under the terms of the agreement, Proteomedix will provide Immunovia with master cells required to produce antibodies related to three of the five biomarkers included in the PancreaSure test and a license for key intellectual property

    9/22/25 8:00:00 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONCO
    SEC Filings

    View All

    Onconetix Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Onconetix, Inc. (0001782107) (Filer)

    9/26/25 8:45:57 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Onconetix Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Onconetix, Inc. (0001782107) (Filer)

    9/22/25 8:37:50 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Onconetix Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Onconetix, Inc. (0001782107) (Filer)

    9/4/25 4:05:41 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONCO
    Leadership Updates

    Live Leadership Updates

    View All

    Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

    Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising

    10/8/24 5:00:00 AM ET
    $ENTO
    $OCS
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONCO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Onconetix Inc.

    SC 13G - Onconetix, Inc. (0001782107) (Subject)

    11/14/24 11:19:35 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Onconetix Inc.

    SC 13D - Onconetix, Inc. (0001782107) (Subject)

    10/1/24 4:35:03 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Onconetix Inc.

    SC 13D - Onconetix, Inc. (0001782107) (Subject)

    10/1/24 4:35:03 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care